Another study showed that targeted m6A therapy mediated by knockdown of ALKBH5 expression participated in and promoted angiogenesis, which may also play a role in HCC, providing a new avenue for combined immunotherapy (61). This evidence concerns the gene ALKBH5 and hepatocellular carcinoma.